tradingkey.logo
tradingkey.logo
Search

Guardant Health Inc

GH
Add to Watchlist
99.940USD
+3.230+3.34%
Close 05/12, 16:00ETQuotes delayed by 15 min
12.49BMarket Cap
LossP/E TTM

Guardant Health Inc

99.940
+3.230+3.34%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

+3.34%

5 Days

+11.64%

1 Month

+27.15%

6 Months

+2.15%

Year to Date

-2.15%

1 Year

+139.89%

TradingKey Stock Score of Guardant Health Inc

Currency: USD Updated: 2026-05-11

Key Insights

Guardant Health Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 20 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 129.07.In the medium term, the stock price is expected to remain stable.The company has been performing well in the stock market over the past month, which is supported by its strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Guardant Health Inc's Score

Industry at a Glance

Industry Ranking
20 / 206
Overall Ranking
94 / 4492
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Guardant Health Inc Highlights

StrengthsRisks
Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 74.13% year-on-year.
Undervalued
The company’s latest PE is -28.40, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 134.76M shares, decreasing 3.46% quarter-over-quarter.
Held by Brandes Investmen
Star Investor Brandes Investmen holds 92.00 shares of this stock.

Analyst Rating

Based on 25 analysts
Buy
Current Rating
129.065
Target Price
+34.86%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Guardant Health Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Guardant Health Inc Info

Guardant Health, Inc. is a precision oncology company focused on guarding wellness and giving every person more time free from cancer. It provides critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and artificial intelligence (AI) analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the treatment for patients with advanced cancer. For patients with advanced-stage cancer, it has developed Guardant360 laboratory developed test (LDT), and Guardant360 CDx test, a comprehensive liquid biopsy test to provide tumor mutation profiling with solid tumors and to be used as a companion diagnostic in connection with non-small cell lung cancer (NSCLC), and breast cancer. It offers other tests, including Guardant360 Tissue test, Guardant Reveal blood test, Guardant360 Response blood test and others.
Ticker SymbolGH
CompanyGuardant Health Inc
CEOTalasaz (Amirali)
Websitehttps://guardanthealth.com/
KeyAI